Board of Directors

The Board of the Company emphasizes the importance of good corporate governance and is aware of its responsibility for overall corporate governance and for supervising the general affairs and business of Faron.

The Board promotes a healthy corporate culture that is based on ethical values and behaviours consistent with Faron’s objectives, strategy and business model described on Faron’s website and with the description of principal risks and uncertainties. As good corporate governance is fundamentally about culture, rather than procedure, Faron’s corporate culture is monitored on a regular basis, and appropriate action is taken if, and to the extent, deemed necessary.

The Chairman of the Board oversees the adoption, delivery and communication of Faron’s corporate governance model. He also endeavours to foster a positive governance culture throughout Faron.

Board of directors

Tuomo Pätsi, MSCI, registered pharmacist

Non-Executive Chairman
Member of the Board since 2023-

Mr. Tuomo Pätsi is a Non-Executive Chairman of Faron Pharmaceuticals Ltd., a role he has served since April 2024 prior joining the Board in March 2023 as a Non-Executive Director. Mr. Pätsi is an experienced biotech and pharmaceutical executive with over 30 years of experience in senior management roles in leading global biopharma companies. Mr. Tuomo Pätsi was the President of International Operations and President of the EMEA region and Worldwide Markets for Celgene Corporation, a global pharmaceutical company and currently wholly owned subsidiary of Bristol Myers Squibb, engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer. Until recently he served as the Executive Vice President for Seagen Inc., a US-based cancer-focused biotechnology company.

Relevant work experience

Rigi-Therapeutics AG, Co-Founder 2023-
Seagen Inc., Executive Vice President, 2020–2022
Celgene Corporation, President of European and International Operations and President of the EMEA region and Worldwide Markets, 2012–2020
Human Genome Science, Vice President of Europe 2010–2012
Amgen Inc., Various positions 1995–2006

Positions of trust

Aurealis Therapeutics AG, a Non-Executive Director, 2024-
Phi Pharma SA, a Non-Executive Director, Chairman, 2024-
Psyon Games Ltd., a Non-Executive Director, 2023-
Aqsens Health Ltd., a Non-Executive Director, 2023-
Notable Labs Inc, a Non-Executive Director, Chairman, 2023-2024

Independence

Independent of the company and its major shareholders.

Shareholdings

31,765 shares and 130,000 stock options, entitling to same amount of shares in the company.

Dr. Markku Jalkanen, Ph.D.

Non-Executive Director
Member of the Board since 2007-

Between 1996 and 2002, Dr. Markku Jalkanen was the founding CEO and President of BioTie Therapies Corp, which became the first publicly traded Finnish biotech company to be listed on NASDAQ. BioTie was sold to Acorda Therapeutics in January 2016 for $363 million.

Dr. Jalkanen obtained a Masters in Medical Biochemistry from the University of Kuopio and subsequently received a Ph.D. in Medical Biochemistry from the University of Turku. He completed a side-laudatur examination in Molecular Biology from the University of Turku and completed his post-doctoral training at Stanford University, California between 1983 and 1986.

Relevant work experience

Faron Pharmaceuticals Oy, CEO, 2007–2024
BioTie Therapies Corp, CEO & President, 1996-2002
Professor, University of Turku, 1992–
Docent in Molecular and Cell Biology, University of Turku, 1992–

Positions of trust

Faron Ventures Oy, Board Member
Inveni Capital, Advisor
Inveni Capital Management, Board Member
Meddia Ltd, Board Member
Priaxon AG, Board Membe

Independence

Dependent of the company and its major shareholders.

Shareholdings

3,413,434 shares (directly and with his spouse) and 540,000 stock options, entitling to same amount of shares in the company.

John Poulos, MBA

Non-executive Director
Member of the Board since 2017-

Mr. John Poulos served as Vice President, Head of Business Development and Acquisitions for AbbVie from 2013 until 2016. He was also Group Vice President, Head of Pharmaceutical Licensing and Acquisitions for Abbott from 2005 until 2012. During his career with AbbVie and Abbott, Mr. Poulos was instrumental in the negotiation of numerous acquisitions, including Knoll/BASF Pharma (Humira) in 2001 for $6.9 billion, Kos Pharmaceuticals in 2006 for $3.7 billion, Solvay in 2010 for $6.2 billion and Pharmacyclics (Imbruvica) in 2015 for $21 billion.

Mr. Poulos holds a B.S. in Marketing and MBA in Finance from Indiana University.

Relevant work experience

GNK Advisors Inc., President, 2016-
AbbVie, Vice President, Head of Business Development and Acquisitions, 2013-2016
Abbott, Group Vice President, Head of Pharmaceutical Licensing and Acquisitions, 2005-2012

Positions of trust

Memgen, Inc., Member of the Board, 2020-

Independence

Independent of the company and its major shareholders.

Shareholdings

No shareholdings and 170,000 stock options, entitling to same amount of shares in the company.

Dr. Marie-Louise Fjällskog, M.D., Ph.D.

Non-executive Director
Member of the Board since 2023-

Dr. Marie-Louise Fjällskog is a professional with extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in the field of clinical oncology, translational research, and drug development.

With over 25 years of clinical experience, Dr. Fjällskog has made significant contributions to the development of targeted therapies for cancer. She has held key roles in various pharmaceutical companies. She also played an instrumental role in the success of Sensei’s $152 million IPO in 2021.

She holds an MD degree and a Ph.D. from Uppsala University, Sweden.

Relevant work experience

Faron Pharmaceuticals, Chief Medical Officer 2022-2023
Associate Professor of Oncology, Uppsala University, Sweden 2008-
Sensei Biotherapeutics, Chief Medical Officer 2020–2021
Merus, VP, Clinical Development 2019–2020
Infinity Pharmaceuticals, position 2018–2019

Positions of trust

Biovica International AB, Board Member 2020–
Lytix Biopharma, Board Member 2021–

Independence

Dependent of the company. Independent of the major shareholders.

Shareholdings

No shareholdings and 210,000 stock options, entitling her to the same number of shares in the company.

Christine Roth

Non-executive Director
Member of the Board since 2023-

Ms. Christine Roth is a pharmaceutical executive with over three decades of experience in the industry. She has played key roles in the development and launch of several therapies, including the first immune-oncology therapy and intentionally designed targeted therapy combinations. Ms. Roth’s expertise extends across various therapy areas, including Oncology, Cardiovascular, Metabolic, and Infectious Diseases. Her career includes leadership positions at major pharmaceutical companies. She holds a bachelor’s degree in chemistry from the University of North Carolina at Chapel Hill.

Relevant work experience

Bayer AG, Head of Global Product Strategy and Commercialization
Bayer AG, Executive Vice President of the Oncology Strategic Business Unit 2022-2024
GSK, SVP Global Oncology Therapy Area
Novartis, VP, 2015-2017
Bristol-Myers Squibb, Director, 2008-2009
GlaxoSmithKline (GSK), US Commercialization Lead, VP, 2010-2015

Positions of trust

American Society of Clinical Oncology, title
American Society of Hematology, title

Independence

Independent of the company and its major shareholders.

Shareholdings

46,075 shares and 60,000 stock options, entitling her to the same number of shares in the company.

The information above is disclosed in accordance with Rule 26 of the AIM Rules for Companies.